Anthony Cheung
Gründer bei ENGENE HOLDINGS INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Anthony Cheung
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Technik-/Wissenschafts-/F&E-Leiter | 24.04.2023 | - |
| Gründer | 24.04.2023 | - | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 16.07.2018 | - | |
| Gründer | - | - | |
| Vorstandsvorsitzender | 25.10.2011 | 16.07.2018 | |
| Präsident | 25.10.2011 | 16.07.2018 | |
| Unternehmenssekretär | 01.01.1999 | 25.05.2011 |
Karriereverlauf von Anthony Cheung
Ausbildung von Anthony Cheung
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistik
International
| Kanada | 4 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- Anthony Cheung
- Erfahrung
